Loading...
•
Dec 31, 2021
Reviva Q4 2021 Earnings Report
Reported financial results for the full year ended December 31, 2021, and summarized recent business highlights.
Key Takeaways
Reviva Pharmaceuticals reported a net loss of $8.5 million, or $0.58 per share, for the year ended December 31, 2021. The company's cash totaled approximately $29.7 million as of December 31, 2021.
First patient dosed in pivotal Phase 3 study and long-term safety trial evaluating brilaroxazine for the treatment of schizophrenia (Jan 2022).
Joined the Russell Microcap® Index as part of the Russel U.S. Indexes annual reconstitution (Jun 2021).
Raised Gross Proceeds of $34.5 Million in Public Offering of Common Stock and Warrants (May 2021).
Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia anticipated in mid-2023.
Forward Guidance
Reviva plans to prioritize near-term efforts and may initiate Phase 2a studies in neuropsychiatric indications, subject to the receipt of additional financing, potentially as early as 2H-2022. Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia anticipated in mid-2023. Pursue partnership opportunities for the development of our pipeline. Evaluate grant and other non-dilutive financing opportunities for our product candidates from Federal and State Healthcare Agencies and Foundations.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...